论文部分内容阅读
骨肉瘤是最常见的原发恶性骨肿瘤,好发于青少年(发病率高达8~11/100万),自然预后极差,严重影响青少年身心健康。新辅助化疗的引入使骨肉瘤患者5年生存率由上世纪70年代前不足20%提高到50%~75%,手术方式由之前截肢发展到80%以上的保肢率,大大改善了患者存活期和生存质量。有效的新辅助化疗已成为手术外最关键的预后影响因素,临床、影像和病理学检查在评价新辅助化疗效果中发挥着不同的作用。影像学检查,尤其MRI扮演了重要的角色,有望成为一种无创、早期且敏感性、特异性较高的活体评价手
Osteosarcoma is the most common primary malignant bone tumor, occurs in adolescents (the incidence of up to 8 ~ 11/1 million), the natural prognosis is very poor, seriously affecting the physical and mental health of adolescents. The introduction of neoadjuvant chemotherapy has improved the 5-year survival rate of osteosarcoma patients from less than 20% to 50% to 75% before the 1970s. Surgical procedures have greatly improved patient survival since the previous limb amputation developed to more than 80% of limb salvage rate Period and quality of life. Effective neoadjuvant chemotherapy has become the most critical prognostic factor outside of surgery, and clinical, imaging and pathological examinations play different roles in the evaluation of neoadjuvant chemotherapeutic effects. Imaging examination, especially MRI plays an important role, is expected to become a non-invasive, early and sensitive, high specificity of living evaluation of the hand